Zhen Han

Also affiliated with City of Hope, Beckman Research Institute

MedicineImmunology and Microbiology

Pilot corpus only

This score is computed over theSindex pilot corpus and does not cover the full scientific literature. Scores are relative to papers we have ingested — papers, authors, and institutions outside the pilot are not represented. Methodology.

Top 100%percentile

0Author DataRank

Indexed papers

0in pilot corpus

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Papers

Driven by 4 papers. Top paper: “MicroRNA Regulation of T-Cell Exhaustion in Cutaneous T Cell Lymphoma”.

MicroRNA Regulation of T-Cell Exhaustion in Cutaneous T Cell Lymphoma

Journal of Investigative Dermatology(2021)10.1016/j.jid.2021.08.447

N/A

0DataRank · unranked

22 citations

Renee Estephan, Xiwei Wu, Chingyu Su, Yate‐Ching Yuan, Hanjun Qin +10 more

Reprogramming of PD-1+ M2-like tumor-associated macrophages with anti–PD-L1 and lenalidomide in cutaneous T cell lymphoma

JCI Insight(2023)10.1172/jci.insight.163518

N/A

0DataRank · unranked

22 citations

Xiwei Wu, Hanjun Qin, Yate‐Ching Yuan, Daniel Schmolze, Chingyu Su +9 more

Blockade of the Immune Checkpoint CD47 by TTI-621 Potentiates the Response to Anti−PD-L1 in Cutaneous T-Cell Lymphoma

Journal of Investigative Dermatology(2023)10.1016/j.jid.2023.02.017

N/A

0DataRank · unranked

20 citations

Xiwei Wu, Hanjun Qin, Yate‐Ching Yuan, Jasmine M. Zain, D. Lynne Smith +5 more

399 | DURVALUMAB AND LENALIDOMIDE SHOWS SUPERIOR EFFICACY OVER SINGLE‐AGENT DURVALUMAB IN REFRACTORY/ADVANCED CUTANEOUS T CELL LYMPHOMA: RESULTS FROM A RANDOMIZED PHASE 2 TRIAL

Hematological Oncology(2025)10.1002/hon.70094_399

N/A

0DataRank · unranked

0 citations

L. CHEN, Xiwei Wu, Zhen Han, Chingyu Su, Yate‐Ching Yuan +7 more